相关临床试验
601
13 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
5
0.8%
已完成
478
79.5%
Enrolling By Invitation
2
0.3%
尚未招募
6
1.0%
招募中
47
7.8%
终止
41
6.8%
Unknown
5
0.8%
撤回
17
2.8%
暂无批准数据
- GeNeuro, Inc., a subsidiary of NRx Pharmaceuticals, has been awarded European Patent EP 3 570 878 B1 covering the anti-HERV K Envelope antibody GNK-301 for ALS. - The patent rests on the finding that the HERV K Envelope protein appears in the spinal fluid of more than 75% of people with ALS and is highly neurotoxic. - GNK-301 was developed with the US National Institute of Neurological Disorders and Stroke under a Cooperative Research and Development Agreement and is now in cGMP manufacture. - GeNeuro plans to begin Phase 1 trials of GNK-301 in ALS patients in the US and Europe in the second half of 2027, pending completion of grant submissions.
- The first patient in the Phase II trial of LMP744 for recurrent glioblastoma has completed the initial treatment cycle without complication, marking an important early milestone. - LMP744 is a novel dual-acting agent that reduces cMyc oncogene overexpression and inhibits topoisomerase 1, with demonstrated blood-brain-barrier penetration in preclinical studies. - The NINDS-conducted trial will enroll 40 first-time recurrent GBM patients, with progression-free survival as the primary endpoint and overall survival as the secondary endpoint. - In prior Phase I studies, over 30% of heavily pretreated patients on single-agent LMP744 experienced stable disease for up to 30 months, with two partial responders observed.
- Researchers identified a panel of 19 blood proteins, including neurofilament light chain (NfL), that can estimate time to ALS symptom onset with an average error of approximately 18 months. - The study analyzed plasma samples from 137 participants in the NIH-funded Pre-symptomatic Familial ALS (Pre-fALS) study using high-throughput proteomic analysis, identifying 92 differentially expressed proteins. - Predictive models were validated across time horizons from six months to five years and produced similar results using UK Biobank data, suggesting broader population relevance. - The findings support the ATLAS clinical trial, which is evaluating tofersen as a preventative therapy in pre-symptomatic ALS carriers in partnership with Biogen.
- Phoenix Nest received a $1.49 million NIH SBIR grant from NINDS to fund manufacturing of JLK-247, a gene therapy for MPS IIIC (Sanfilippo syndrome type C). - The funding will support production of a 500-liter cGMP vector batch and analytical development ahead of a planned Phase I clinical trial. - MPS IIIC is an ultra-rare pediatric neurodegenerative disease with no approved therapies, caused by HGSNAT enzyme deficiency leading to heparan sulfate accumulation. - Because the deficient enzyme is membrane-bound within lysosomes, conventional enzyme replacement therapy is not viable, making gene therapy one of the few potential treatment modalities.
- Oswald Steward of UC Irvine shares the 2026 Kavli Prize in Neuroscience with three other researchers for discovering local protein translation at synapses. - His electron microscopy studies revealed that neurons produce proteins locally where needed, transforming understanding of brain plasticity, learning, and memory. - The discovery has advanced research into fragile X syndrome, autism spectrum disorder, ALS, and brain and spinal cord injury. - The prize, administered by the Norwegian Academy of Science and Letters, includes $1 million and will be presented at a September ceremony in Oslo.
- Researchers used optogenetic stimulation to induce NREM sleep-like neural activity in localized brain regions of awake, sleep-deprived mice, effectively mimicking the restorative effects of sleep. - The rhythmic on-and-off firing pattern, not overall reduction in neuronal activity, was identified as the critical mechanism driving sleep's restorative benefits for memory consolidation. - Sleep-deprived mice receiving bilateral stimulation performed on par with well-rested controls in tactile memory tests, while non-stimulated sleep-deprived mice showed significant impairment. - The findings open translational avenues for non-invasive transcranial stimulation technologies in humans to potentially prevent and treat cognitive decline.
- The National Institutes of Health discontinued the low-dose rivaroxaban arm of the CAPTIVA stroke prevention trial following safety concerns and evidence of treatment futility. - The Data Safety and Monitoring Board recommended halting the rivaroxaban treatment due to increased safety events in patients with intracranial arterial stenosis. - The CAPTIVA trial continues with two remaining treatment arms, comparing ticagrelor and clopidogrel combinations against standard care in up to 1,683 participants. - This development highlights ongoing challenges in developing effective anticoagulation strategies for stroke prevention in patients with severe intracranial atherosclerosis.
- NIH-funded preclinical research demonstrates that uric acid treatment significantly improved sensorimotor function and survival rates in rodents 30 days after ischemic stroke. - The study, conducted by University of Iowa researchers, showed efficacy across diverse animal groups including different ages, sexes, and those with comorbidities like obesity and hypertension. - As part of the NIH's Stroke Preclinical Assessment Network (SPAN), uric acid emerged as the only effective agent among six promising stroke treatments tested, suggesting readiness for human clinical trials.
- The University of Virginia has secured a $9.3 million NIH grant as initial funding for a $30 million clinical trial investigating ketamine's potential in treating status epilepticus, a life-threatening seizure condition. - Current standard treatments for status epilepticus are only effective in approximately 47% of adults and 52% of children, highlighting a critical need for improved therapeutic approaches. - The KESETT trial will evaluate two different ketamine dosages (1mg and 3mg) as add-on therapy to existing treatments across approximately 60 sites, focusing particularly on outcomes in children aged 1 year and older.
- A recent study indicates that newer anti-seizure medications, like lamotrigine and levetiracetam, pose no significant risk to children's language development when taken during pregnancy. - The research followed 387 children up to age 6, assessing their verbal abilities and finding no difference between those exposed to the drugs in utero and those who were not. - Findings suggest that controlling seizures with newer medications during pregnancy is a safe approach, contrasting with older medications like valproate, which have known risks. - The study also highlights the potential benefits of folate supplementation during early pregnancy for improved cognitive and behavioral outcomes in children.
